# Alector (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/alector-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 71.3 |
| Citations | 20,612 |
| City | San Francisco |
| Country | US |
| Description | Alector (United States) is a research organisation in San Francisco, US. OpenAlex records 179 works and 20,612 citations for it. 116 researchers list it as their most recent affiliation. |
| Homepage | https://alector.com |
| OpenAlex ID | https://openalex.org/I4210152456 |
| Region | California |
| Researchers | 116 |
| ROR ID | https://ror.org/03vagve85 |
| Type | company |
| Works | 179 |

## University papers

Showing 12 of 23.

- [Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer](https://scholariq.org/papers/paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-gefitinib-an-inhibitor-of-the-epidermal-growth-factor-receptor/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tribute-a-phase-iii-trial-of-erlotinib-hydrochloride-osi-774-combined-with/)
- [Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability](https://scholariq.org/papers/selective-requirement-for-src-kinases-during-vegf-induced-angiogenesis-and/)
- [Elevated body mass index is associated with executive dysfunction in otherwise healthy adults](https://scholariq.org/papers/elevated-body-mass-index-is-associated-with-executive-dysfunction-in-otherwise/)
- [Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial](https://scholariq.org/papers/atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced/)
- [Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model](https://scholariq.org/papers/anti-human-trem2-induces-microglia-proliferation-and-reduces-pathology-in-an/)

## University researchers

- [Robert Paul](https://scholariq.org/researchers/robert-paul/)

## University top topics

Showing 8 of 25.

- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Neuroinflammation and Neurodegeneration Mechanisms](https://scholariq.org/topics/neuroinflammation-and-neurodegeneration-mechanisms/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Inflammation biomarkers and pathways](https://scholariq.org/topics/inflammation-biomarkers-and-pathways/)
- [Dementia and Cognitive Impairment Research](https://scholariq.org/topics/dementia-and-cognitive-impairment-research/)
- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Neurological Disease Mechanisms and Treatments](https://scholariq.org/topics/neurological-disease-mechanisms-and-treatments/)
- [Bioinformatics and Genomic Networks](https://scholariq.org/topics/bioinformatics-and-genomic-networks/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.